Oncology

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized endocrine therapies…

Patients with cancer often have a compromised immune system, which places them at an increased risk of infection that can extend beyond…

Mutations in HER2, also known as ERBB2, represent a distinct molecular subset of NSCLC, occurring in approximately 2–4% of cases, and are…

EpNECs are considered rare and are often associated with a poor prognosis, with up to 85% of patients presenting with advanced…

Hepatocellular carcinoma (HCC) is frequently diagnosed at an advanced stage, when most patients have underlying cirrhosis. Prognosis is…

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, characterized by the…

Despite improved screening and treatment in developing nations, cervical cancer continues to have a global incidence of approximately…

Neuroendocrine tumors (NET) constitute a heterogeneous group of neoplasms that originate from cells of the diffuse neuroendocrine system…